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Abstract 
Introduction: Nifedipine is a BCS Class II drug used for treatment of hypertension and preterm 
labor. Large inter-patient variability in nifedipine absorption results in variable exposure among 
different patients. Methods and Materials: We conducted in vitro dissolution studies to 
compare nifedipine dissolution from immediate release (IR) capsules with different volumes of 
dissolution media. Results from dissolution studies were used to design a cross-over study in 
healthy volunteers to evaluate the effect of co-administered water volume with nifedipine 10 
mg IR capsules on nifedipine pharmacokinetics, especially absorption (Cmax, tmax, and AUC0-6). 
Results and Discussion: Dissolution studies demonstrated that larger gastric fluid volumes 
result in enhanced nifedipine dissolution from 10 mg IR cosolvent capsules (73% vs. 17% in 200 
and 100 mL simulated gastric fluid, respectively, at 30 min). The pharmacokinetic crossover 
study in healthy volunteers (N=6) did not show a significant effect of the water volume 
administered with the capsule (50 vs. 250 ml) on Cmax, tmax, or AUC0-6 of orally administered 
nifedipine IR capsules (10 mg). However, administration of large water volumes resulted in 
lower variability in nifedipine Cmax (47% vs.70% for 250 mL and 50 mL, respectively). Conclusion: 
Administration of large water volumes with nifedipine 10 mg IR cosolvent capsules reduces 
inter-individual variability in plasma exposure. Evaluation of similar effects in other BCS Class-II 
drugs is recommended. 
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Introduction 
Biopharmaceutics Classification System (BCS) Class II drugs have low solubility and high 
intestinal permeability. Due to their low solubility, the in vivo dissolution rate for these drugs 
can be a rate-limiting step for absorption through the gastrointestinal (GI) tract. (1) Enhanced in 
vivo dissolution through innovative formulations or increased GIT fluid volumes may be 
important to ensure adequate and consistent absorption of these drugs. Nifedipine is a BCS 
Class II drug used for treatment of hypertension (2) and preterm labor. (3) Nifedipine in the 
immediate release (IR) form is recommended by the American College of Obstetrics and 
Gynecology (ACOG) for the treatment of preterm labor. (4) Despite nifedipine being one of the 
first-line therapies for preterm labor (5-8), there is high inter-patient variability in exposure and 
response, resulting in lack of efficacy in some patients. (6)   
Nifedipine is primarily eliminated through CYP3A metabolism (9) with an elimination half-life of 
1.25-2 hours in healthy individuals. (10) Given its low solubility, nifedipine absorption is highly 
variable and its bioavailability ranges from 50 to 70%. (11) Absorption also depends on the 
dosage form used. (12) While extended release forms are commonly used for long-term 
treatment of hypertension, IR capsules are used for the acute treatment of preterm labor. 
These IR capsules are typically liquid-filled cosolvent formulations in which the drug is 
solubilized. Despite the drug being administered as a solution, high inter-patient variability 
during the absorption phase has been reported. (12) In a previous study of nifedipine 
pharmacokinetics in 14 pregnant women, dose-corrected Cmax (maximum observed plasma 
concentration) ranged from 41 to 397 µg/L. (13)  
4 
 
Administration of different doses of nifedipine IR capsules also results in variable absorption 
profiles. Administration of nifedipine IR 20 mg capsules has been shown to result in 
proportional increase in AUC (area under the plasma concentration time curve) but less than 
proportional increase in Cmax as compared to doses of 5 and 10 mg, possibly due to reduced 
absorption rate. (11) Thelen and colleagues attributed this to drug precipitation in the stomach. 
(14) However, this hypothesis has not been tested in prospective clinical trials.  
Investigation of the rate and extent of in vitro drug dissolution in physiologically-relevant 
dissolution fluids can be used to try and understand and predict in vivo absorption profiles. 
Fasted-state simulated gastric fluid (FaSSGF) has been shown to provide the closest 
composition (sodium taurocholate, pepsin, lecithin, sodium chloride, and HCl) to human gastric 
contents (15-17) and dissolution studies in FaSSGF can be used to investigate factors affecting 
drug dissolution prior to evaluation in humans. 
The objectives of our studies were to evaluate the effect of gastric fluid volume on nifedipine in 
vitro dissolution and in vivo pharmacokinetics. We conducted in vitro and clinical studies to test 
the hypothesis that small gastric fluid volumes will lead to reduced nifedipine dissolution in 
vitro and decreased and/or delayed absorption in humans. 
 
Methods 
Determination of Nifedipine Equilibrium Solubility  
Nifedipine equilibrium solubility was determined in vitro using different fluids to evaluate the 
effects of fluid composition and pH on nifedipine solubility. Various fluids simulating gastric and 
intestinal pH were used to predict nifedipine solubility in the stomach and small intestine. 
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Nifedipine solubility was studied in FaSSGF (sodium taurocholate (80 µM), pepsin (0.1 mg/ml), 
lecithin (20 µM), sodium chloride (0.2%), HCl (to adjust pH to 1.6), and distilled water) (16), 0.01 
M HCl, and 0.05 M phosphate buffer (pH 6.5). All chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). 
Nifedipine equilibrium solubility was determined in each of the three fluids by adding excess 
drug to the media and constant shaking in a 37°C water bath with protection from light 
throughout the duration of the experiment. Samples were collected at 12, 24, 36, 48, and 72 
hours. Collected samples were immediately centrifuged at 5000 rpm for 10 minutes and the 
clear supernatant was aspirated and stored at -20°C until analysis.  
Nifedipine concentrations were determined by HPLC (Agilent 1100, Agilent Technologies®, 
Santa Clara, CA, USA) coupled with a UV detector (λ = 240 nm) and using diazepam as an 
internal standard. Analytes were separated on a C18 column 5 µm, 4.6 x 15 mm column 
(Phenomenex) with isocratic mobile phase consisting of 35% acetonitrile, 17% methanol and 
48% water at a flow rate of 1.2 ml/min. The lower limit of quantification for nifedipine was 0.2 
mg/L. Interday and intraday coefficients of variation were less than 15%.  
 
Nifedipine Dissolution Profiles 
Dissolution of nifedipine from IR capsules (Nifedipine Actavis®, Actavis Elizabeth LLC, NJ, USA) 
was studied in FaSSGF. Experiments were conducted to evaluate the effect of various nifedipine 
doses and simulated gastric fluid volumes on nifedipine in vitro dissolution: 10 mg IR capsule in 
100 mL FaSSGF (“10/100”), 10 mg IR capsule in 200 mL FaSSGF (“10/200”), 20 mg (2x10 mg IR 
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capsules) in 200 mL FaSSGF (“20/200”), and 20 mg (2x10 mg IR capsules) in 400 mL FaSSGF 
(“20/400”). 
Dissolution experiments were conducted using a USP-II paddle apparatus (SR8PLUS Dissolution 
test station, Hanson Virtual Instruments, San Jose, CA, USA). A standardized mini-paddle 
apparatus using smaller paddles and 200-mL vessels was used for experiments performed with 
100 and 200 mL of media. Dissolution fluid (FaSSGF) was prepared as described above and was 
maintained at 37±0.5°C during the experiment. The apparatus was protected from light 
throughout the experiment. A paddle speed of 75 rpm was used since this has been shown to 
provide a high similarity in drug release profiles between the standard paddle and mini-paddle 
apparatus for most immediate release dosage forms. (18)  
Dissolution experiments were started by adding one or two 10 mg IR capsules to the dissolution 
vessels filled with the appropriate volume of FaSSGF. Samples (0.5 ml) were collected at 10, 15, 
20, 30, 45, and 60 minutes after the start of the experiment. A sampling cannula with an 
attached 10 µm porous full flow filter (FIL010-HR, Quality Lab Accessories, Telford, PA, USA) 
was placed in each vessel and was used to collect and filter the samples without stopping the 
experiment. Samples were stored at -20°C until analysis (as described above). The percentage 
of the total dose dissolved at each time point was calculated for each of six replicates and a 
mean percentage dissolved was obtained for each time point.  
 
Effects of Coadministered Water Volume on Nifedipine Absorption in Humans 
The effect of water volume administered orally with nifedipine IR capsules on nifedipine 
pharmacokinetics was evaluated in a prospective clinical trial. The trial was designed as a pilot 
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study to compare nifedipine pharmacokinetics, primarily absorption, after administration of IR 
capsules with small and large volumes of water.  
The study design and all study procedures were approved by the Indiana University-Purdue 
University at Indianapolis (IUPUI) Institutional Review Board. Study procedures were conducted 
in the Indiana Clinical Research Center (ICRC) (part of the Indiana Clinical and Translational 
Sciences Institute) at Indiana University Hospital (Indianapolis, IN) and all participants provided 
written informed consent. 
 
Inclusion/Exclusion Criteria 
Healthy adults (18-45 years) were eligible for enrollment in the study if they were not pregnant 
or lactating, had baseline systolic and diastolic blood pressures of at least 100 and 60 mm Hg, 
respectively, had normal hemoglobin (12-15 g/dl for female and 14-18 g/dl for male subjects) 
and hematocrit (35-49% for female and 40-54% for male subjects), had no history of allergy or 
hypersensitivity to nifedipine, had no significant clinical illness within a two week period 
preceding each study phase, had no cardiac, renal, hepatic, gastrointestinal, psychiatric or other 
diseases, and had no history of drug addiction and/or alcohol abuse. Administration of any 
medication (prescription or over the counter, except for oral contraceptives), herbal/botanical 
supplement, or investigational drug was prohibited within a three week period preceding each 
study phase. 
 
Study Design and Procedures 
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Subjects were asked to avoid alcohol consumption and smoking for 24 hours before and 
throughout the study phases and to avoid eating or drinking grapefruit, grapefruit juice, and 
citrus juices for 48 hours before and throughout the study phases. Subjects were also instructed 
to fast for 10 hours and to avoid consumption of water for 3 hours prior to admission to ICRC.  
Following baseline blood draws, subjects took a 10 mg nifedipine IR capsule (Nifedipine 
Actavis®, Lot No. 363G12; Actavis Elizabeth LLC, NJ, USA) orally with either 50 mL (small 
volume) or 250 mL (large volume) of water. The volume of water administered on the large 
volume phase was chosen as it is similar to commonly used water volumes in clinical trials of 
oral dosage forms in healthy volunteers (240-250 ml). A volume of 50 ml was chosen for the 
small volume phase as the minimum volume deemed by the study investigators to allow easy 
administration and complete swallowing of the nifedipine capsules. The order of the two 
phases was randomized and they were separated by a wash out period of at least 2 days.  
Blood samples (2 ml) for determination of nifedipine plasma concentrations were collected in 
EDTA-treated blood collection tubes before and 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 4, and 6 hours 
following administration of nifedipine. Samples were immediately centrifuged at 2000 rpm for 
7 min at 4oC, and plasma transferred to polypropylene tubes for storage at –80oC until analyzed 
by LC/MS/MS by the Clinical Pharmacology Analytical Core Laboratory at Indiana University as 
described previously. (19) The assay was linear between 0.01 and 1000 ng/mL and inter- and 
intra-day coefficients of variation were <15%. Heart rate and blood pressure were monitored 
every 30 min for the first 2 hours and at 4 and 6 hours following nifedipine dose administration. 
Lunch (excluding food containing citrus or grapefruit) was provided 3 hrs after nifedipine 
administration.  
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Pharmacokinetic Analyses 
A non-compartmental pharmacokinetic analysis (NCA) was performed using Microsoft Office 
Excel 2007© (Microsoft Corporation, Redmond, WA) PKSolver add-in (20) to determine each 
subject’s nifedipine Cmax, tmax (time for maximum plasma concentration), and AUC0-6 for each of 
the two phases. Cmax and tmax were observed from the individual plasma concentration time 
profiles and AUC0-6 was estimated by PKSolver add-in using nifedipine dose and observed 
concentration-time profiles. 
 
Statistical Analyses 
For determination of Nifedipine equilibrium solubility, nifedipine concentrations were 
compared between the three dissolution fluids at each time point using one-way ANOVA 
(α=0.05) with Bonferroni’s posthoc test for pairwise comparisons. For dissolution experiments, 
the mean area under nifedipine dissolution curve (AUCdiss) was compared between the 10/100 
and 10/200 experiments and the 20/200 and 20/400 experiments using unpaired Student’s t-
test (α=0.05). In addition, the effect of fluid volume on percent of nifedipine dose dissolved 
after 20, 30, 45, and 60 minutes was compared using repeated measures ANOVA with posthoc 
Bonferroni comparisons. 
The sample size for the cross-over study was estimated from the variance observed in 
nifedipine Cmax by Yu and colleagues (21), in which the average (±SD) nifedipine Cmax after a 10 
mg dose was 124 (±52) ng/ml. Based on this, we determined that six subjects were needed to 
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detect a 60% difference in the mean nifedipine Cmax between the two phases, with an alpha of 
0.05 and power of 90%. Pharmacokinetic parameters estimated from the NCA for the two 
phases were compared using a paired Student’s t-test for normally distributed data and 
Wilcoxon signed rank test for non-normally distributed data (SPSS®; Version 21.0. Armonk, NY: 
IBM Corp.). 
Results  
Determination of Nifedipine Equilibrium Solubility  
 
 
Equilibrium solubility of nifedipine was achieved within 24 hours and determined to be 10.91± 
2.27, 9.58±1.34 and 7.47±1.35 µg/mL in 0.01 M HCl, FaSSGF and pH 6.5 phosphate buffer, 
respectively. Nifedipine concentrations were similar between the dissolution fluids after 24 
hours (P>0.05, one-way ANOVA). Based on these results, it was concluded that nifedipine 
solubility is likely to be constant across the GI tract and does not change between gastric and 
intestinal pH. Further dissolution experiments of nifedipine capsules were conducted in FaSSGF 
which most closely simulates gastric fluid.  
 
Fluid Volume Effect on Nifedipine in Vitro Dissolution  
 
Nifedipine dissolution from IR capsules was determined using 10 and 20 mg of nifedipine in 
varying volumes of FaSSGF. Nifedipine 10 mg capsules dissolved to a greater extent in in 200 mL 
FaSSGF (10/200) compared to 100 mL (10/100) (Figure 1). The percentage of nifedipine 
dissolved was significantly higher in the 10/200 compared to the 10/100 experiment at all of 
the time points studied: 20 min (72.1±4.2% vs. 23.3±7.6%, p=0.003); 30 min (73.4±5.8% vs. 
17.3±1.1%, p=0.003); 45 min (60.4±4.3% vs. 18.6±2.9%, p=0.01); and 60 min (49.3±6.1% vs. 
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17.2±1.2%, p=0.02). AUCdiss was more than 3-fold higher in the 10/200 experiment compared to 
10/100 (51.1±1.8 vs. 15.8±2.1 ng.hr/ml, P<0.001).  
Conversely, dissolution of 20 mg of nifedipine was not consistently higher in 400 mL as 
compared to 200 mL of FaSSGF (Figure 2). The percentage of nifedipine dissolved in the 400 mL 
solution was significantly higher only at 60 min (39.3±5.1% vs. 21.6±6.9%, P=0.03). Although, 
AUCdiss was significantly higher in the 20/400 experiment as compared to 20/200 (30.3±7.5 vs. 
17.4±2.9 ng.hr/ml, P=0.003), the magnitude of difference was less than that seen with the 10 
mg capsule at different fluid volumes (1.7-fold vs. 3.2 -fold).  
 
Effects of Coadministered Water Volume on Nifedipine Absorption in Humans 
A prospective randomized two-phase crossover clinical trial was conducted to evaluate the 
effect of coadministered water volume on pharmacokinetics of IR nifedipine capsules. A 
nifedipine dose of 10 mg was used for the clinical trial based on results from in vitro dissolution 
studies that showed a more pronounced effect of fluid volume on 10 mg than on 20 mg. 
 
Six healthy volunteers (4 men and 2 women) enrolled in and completed the two phases of the 
study. One subject was a cigarette smoker and two consumed alcohol occasionally, but all 
abstained from alcohol and smoking for 24 hours before and during each study phase. Table 1 
lists the demographic characteristics for the six subjects at the time of enrollment. 
 
Table 1. Baseline demographic characteristics for study subjects (N=6). 
 
Demographic Characteristic Mean±SD/Number  
Male/Female 4/2 
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Age (yrs) 29±10 
Weight (kg) 70±5 
Height (cm) 173±6 
Race 4 Caucasian 
2 African American 
Baseline Heart Rate (bpm) 73±14 
Baseline Systolic Blood Pressure (mm Hg) 123±10 
Baseline Diastolic Blood Pressure (mm Hg) 71±8 
 
The effect of coadministered water volume on nifedipine pharmacokinetics during the 
absorption phase was evaluated by comparing each subject’s Cmax, tmax, and AUC0-6 between the 
two phases (Figure 3). There was high interindividual variability in the effect of 50 vs. 250 mL of 
coadministered water volume on nifedipine pharmacokinetic parameters. Plasma 
concentration-time profiles for three of the six subjects showed substantially higher nifedipine 
concentrations during the large volume phase compared to the small volume phase (Figure 4). 
In those subjects, the large volume phase was associated with 2-, 6.5-, and 10-fold increase in 
Cmax and 1.5-, 1.8-, and 2-fold increase in AUC0-6. Two of the six subjects had similar nifedipine 
concentrations in the two phases with minimal change in Cmax or AUC0-6. On the other hand, 
one subject had higher nifedipine plasma concentrations during the small volume phase with 7- 
and 2-fold increase in Cmax and AUC0-6, respectively. Median tmax was similar between the two 
phases of the study (0.5 hours) with a range of 0.25-0.75 and 0.5-0.75 for the small and large 
volume phases, respectively. Table 2 summarizes the nifedipine pharmacokinetic parameters 
for each of the six subjects. Comparison of nifedipine pharmacokinetic parameters between the 
two phases resulted in no significant differences between the phases in any of the parameters. 
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No subject experienced any clinical adverse event due to changes in blood pressure or heart 
rate; although the study was not primarily designed to assess pharmacodynamic changes in a 
healthy volunteer population. 
Table 2. Nifedipine individual pharmacokinetic parameters for each of the two study 
phases.  
 
Subject Number 
(Sex, Race, Age, Weight) 
Cmax (ng/ml) AUC0-6 (ng.hr/ml) 
Small 
Volume 
Large 
Volume 
Small 
Volume 
Large 
Volume 
1 (M, C, 24, 71) 118.1 102.7 135.7 149.2 
2 (M, AA, 23, 71) 10.81 111.8 
77.14 157.1 
3 (M, AA, 18, 71) 96.06 13.92 
135.9 61.19 
4 (F, C, 33, 76) 113.7 97.87 
150.3 137.1 
5 (M, C, 45, 67) 11.61 71.19 
45.3 80.59 
6 (F, C, 28, 62) 66.64 133.9 
99.19 147.8 
Geometric Least Squares 
Mean 
47.0 72.8 99.3 115.2 
Geometric Least Squares 
Mean Ratio   (90% CI)  
0.65 (0.18-2.29) 
0.86 (0.55-1.35) 
           CI: Confidence Interval, M: Male, F: Female, C: Caucasian, AA: African American 
 
Discussion 
As a BCS Class II drug, nifedipine absorption is known to be highly variable and dependent on 
the dosage form used. (12) While the majority of nifedipine is prescribed as an extended 
release formulation, the obstetric community continues to employ IR nifedipine as a first-line 
treatment for preterm labor. (22) However, large variability in nifedipine pharmacokinetics and 
tocolytic effects prevents it from being effective in all cases of preterm labor. For example, 
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observed nifedipine concentrations in 14 pregnant women treated for preterm labor showed a 
10-fold range in dose-corrected Cmax. (13) 
Several factors may contribute to the observed variability in nifedipine absorption. First, 
variability in nifedipine dissolution within the GI tract may result in different fractions of the 
dose being available for absorption at different times and locations within the GI tract. Second, 
differences in CYP3A-mediated first-pass metabolism may result in variability in nifedipine 
absorption. However, this is unlikely to be the major factor contributing to differences in 
absorption rates since differences in first-pass metabolism usually affect oral bioavailability and 
not the absorption rate.  
 
We conducted a series of in vitro dissolution studies and a pilot clinical study to describe the 
dissolution and absorption of nifedipine. Our dissolution studies demonstrate a significant 
increase in the dissolution of 10 mg nifedipine IR capsule with larger dissolution media volume. 
Increasing the volume of FaSSGF used in dissolution experiments from 100 to 200 mL resulted 
in more than three-fold increase in AUCdiss and significantly higher percentages of nifedipine 
dissolved at all of the time points. Since the solubility in the dissolution media is lower than the 
concentrations achieved, a supersaturated system has been formed. Supersaturated systems 
undergo precipitation, which explains the observed peak followed by decline in cumulative 
nifedipine dissolved.  A supersaturated system emerges here since the dosage form is a 
cosolvent-based formulation. Upon exposure to aqueous media, drug concentrations exceed 
equilibrium solubility in the cosolvent/ aqueous system and supersaturation is observed. The 
larger the volume of dissolution media, the higher the degree of supersaturation observed. (18) 
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A significant improvement in nifedipine dissolution with higher volumes was also observed with 
20 mg doses although the magnitude of change was much smaller (1.7-fold increase in AUCdiss) 
than that observed with 10 mg doses. These findings suggest that the effect of fluid volume on 
nifedipine absorption from 20 mg doses may not be easily observed in vivo since a substantial 
increase in volume beyond 400 mL may be needed to induce a significant improvement in 
dissolution. Given the substantial improvement in dissolution of 10 mg doses with the increase 
in gastric volume to only 200 ml; the effect of fluid volume on nifedipine absorption in vivo was 
studied with this dose.  
 
Using a randomized cross-over design, we evaluated the effect of co-administered water 
volume (50 and 250 ml) on nifedipine Cmax, Tmax, and AUC0-6 in healthy volunteers. Overall, 
nifedipine pharmacokinetic parameters did not significantly differ between the two phases of 
the study. However, there was wide variability between individuals in response to change in 
fluid volume. The a priori sample size calculation was based on a previously reported variability 
in nifedipine Cmax of 42%. (21) However, in our study, we observed a much higher variability (up 
to 70%), which may have resulted in a lack of power to detect a significant difference between 
the two phases.  
A more detailed investigation of the effect of fluid volume in individual subjects was conducted 
to provide some insight into its possible role in nifedipine absorption. Plasma concentration-
time profiles for three of the six subjects showed substantially higher nifedipine concentrations 
during the large volume phase. This is consistent with the results obtained from the in vitro 
dissolution studies which indicated increased dissolution in 200 mL vs. 100 mL of fluid. In these 
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three individuals, nifedipine dissolution was increased in the presence of additional water, 
leading to higher availability of drug for absorption within the first six hours. 
 
For two of the six subjects enrolled in the study, Cmax and AUC0-6 were similar between the two 
study phases, indicating no effect of water volume on the observed concentration-time profiles. 
Both subjects had concentration-time profiles and Cmax on the small volume phase similar to 
what would be expected for the large volume phase. This lack of effect is inconsistent with the 
effect seen in the in vitro dissolution studies. However, it is possible that these individuals had 
larger than average residual intragastric volumes in the fasted state, which may result in 
adequate dissolution even with small volume of coadministered water. Although the average 
basal gastric fluid volume in the fasted state is usually 50 mL (23), a larger volume in a specific 
subject is possible due to physiological inter-individual variability or inter-occasion variability 
within the same subject. Additionally, it is possible that these subjects did not comply with pre-
study instructions and consumed extraneous fluids prior to the study visit.  
 
Plasma concentration-time profiles observed in the sixth subject in our study showed an effect 
of fluid volume opposite to what would be expected based on our initial hypothesis and the 
results of the dissolution studies (higher concentrations during low volume phase). The 
unexpectedly high nifedipine exposure in the small volume phase can be explained by one or 
both of the reasons discussed above. However, the substantially low nifedipine exposure in the 
large volume phase cannot be similarly explained by variability in intragastric fluid volume. 
Given the relatively small number of subjects in this pilot study and the substantial variability in 
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nifedipine absorption, larger future studies are needed to further evaluate the impact of 
coadministered water volume on nifedipine PK from IR capsules and assess the reproducibility 
of current findings in a larger sample size. 
 
Effects of nifedipine on blood pressure in women with preeclampsia have been shown to 
correlate with plasma concentrations with nadirs of blood pressure occurring at the same time 
of Cmax. (24) Consequently, clinically significant variability in tocolytic or blood pressure 
reducing effects may be expected as a result of variability in nifedipine Cmax. The administration 
of large volume of water was associated with a smaller variability in observed Cmax (CV% = 47% 
versus 70% for small volume phase). Further, if we exclude the subject who had low nifedipine 
exposure on the large volume phase, the reduction in variability with the large water volume 
was even more pronounced (CV% = 22% versus 81% for small volume phase).  
 
Previous studies have investigated the effect of coadministered water volume on the 
pharmacokinetics of BCS Class II drugs in humans. In 1978, Welling et al. investigated the effect 
of food and coadministered water volume on the bioavailability of erythromycin in healthy 
volunteers using erythromycin stearate film-coated tablets. The results of their study showed 
that higher and more uniform systemic concentrations of erythromycin were achieved when 
the coadministered water volume was increased from 20 to 250 ml. (25) In 1984, Bustrack et al. 
studied digoxin bioavailability from tablets and capsules following coadministration with 30 or 
240 mL of water. Their study, however, did not show an effect of coadministered water volume 
on digoxin Cmax or AUC0-12. (26) Differences in bioavailability between digoxin and erythromycin 
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may explain the different results obtained in those two studies. Digoxin bioavailability from 
tablets and capsules (70-80%) is higher than that for erythromycin from erythromycin stearate 
tablets (30%). (27, 28) Low erythromycin bioavailability can result in more pronounced effects 
of larger coadministered water volumes than that observed with digoxin where bioavailability is 
already relatively high. The lack of effect of coadministered water volume on overall nifedipine 
PK parameters in some subjects may be due to the relatively higher nifedipine bioavailability 
from IR capsules (50-70%) as compared to erythromycin. (11) 
 
Overall, our pilot study results indicate that administration of large water volume (250 ml) with 
10 mg doses of nifedipine IR cosolvent capsules may reduce the variability in observed Cmax, 
which, if confirmed in larger future studies, may warrant the use of large fluid volumes when 
nifedipine IR capsules are administered for treatment of preterm labor.  Low solubility may play 
a role in limiting or delaying GI absorption of BCS Class II drugs and future studies with other 
BCS Class II drugs are needed to evaluate the applicability of the current findings to other low 
solubility drugs with different formulations. 
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Figure 1. Dissolution of 10 mg nifedipine capsule in 100 mL (A) and 200 mL (B) of FaSSGF. Grey 
lines and dots represent individual dissolution profiles for each of the six experiments. Black 
line and dots represent the mean dissolution profile for all six experiments and the error bars 
represent standard deviation. 
 
Figure 2. Dissolution of 20 mg nifedipine (two 10 mg capsules) in 200 mL (A) and 400 mL (B) of 
FaSSGF. Grey dashed lines and grey dots represent individual dissolution profiles for each of the 
six experiments. Black solid line and black dots represent the mean dissolution profile for all six 
experiments and the error bars represent standard deviation. 
 
Figure 3. Nifedipine plasma concentration time profiles for subjects with 
coadministration of small (50 mL; circles and solid lines) and large (250 mL; 
triangles and dot-dashed lines) volumes of water. 
 
Figure 4. Change in nifedipine Cmax (A) and AUC0-6 (B) between the two study phases 
for each of the six subjects.
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